Phenotypes Associated with This Genotype

Genotype
MGI:4460268

• Allelic Composition: Msh2^tm1Rak/Msh2^tm2.1Rak; Tg(Vil1-cre)20Syr/0
• Genetic Background: involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * DBA/2 * SJL

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

neoplasm

increased gastrointestinal tumor incidence ( J:161577 )

• beginning at 6 months, mice develop intestinal tumors

• by 10 months, 50% of mice develop intestinal tumors

increased intestinal adenocarcinoma incidence ( J:161577 )

• 82% of tumors

increased intestinal adenoma incidence ( J:161577 )

• 18% of tumors

abnormal tumor morphology ( J:161577 )

• mice develop fewer and larger tumors than in Msh2^tm2.1Rak/Msh2^tm3.1Wed Tg(Vil-cre)20Syr mice

• tumors do not respond to treatment with cisplatin or FOLFOX unlike tumors from Msh2^tm2.1Rak/Msh2^tm3.1Wed Tg(Vil-cre)20Syr mice

homeostasis/metabolism

abnormal mismatch repair ( J:161577 )

• tumor cells exhibit increased microsatellite instability compared with wild-type cells

abnormal physiological response to xenobiotic ( J:161577 )

• tumors do not respond to treatment with cisplatin or FOLFOX unlike tumors from Msh2^tm2.1Rak/Msh2^tm3.1Wed Tg(Vil-cre)20Syr mice

• FOLFOX-treated intestinal mucosa exhibit decreased apoptosis compared with similarly treated cells from Msh2^tm2.1Wed homozygotes and Msh2^tm2.1Rak/Msh2^tm3.1Wed Tg(Vil-cre)20Syr mice

cellular

abnormal mismatch repair ( J:161577 )

• tumor cells exhibit increased microsatellite instability compared with wild-type cells

digestive/alimentary system

increased gastrointestinal tumor incidence ( J:161577 )

• beginning at 6 months, mice develop intestinal tumors

• by 10 months, 50% of mice develop intestinal tumors

increased intestinal adenocarcinoma incidence ( J:161577 )

• 82% of tumors

increased intestinal adenoma incidence ( J:161577 )

• 18% of tumors

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
Lynch syndrome		DOID:3883	OMIM:PS120435	J:161577